Compounds and methods for treating neurological and cardiovascular conditions

Patent metadata

Field	Value
Publication number	US-10265338-B2
Application number	US-201715670738-A
Country	US
Kind code	B2
Filing date	Aug 7, 2017
Priority date	Apr 21, 2016
Publication date	Apr 23, 2019
Grant date	Apr 23, 2019

Abstract

The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

First claim

We claim:

1. A method of treating a brain or central nervous system (CNS) injury or condition comprising administering to a patient in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable composition thereof;
wherein the brain or CNS injury or condition is selected from radiation damage, migraine headache, ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, or transient ischemic attacks (TIA).

2. The method of claim 1 , wherein the compound is

3. The method of claim 1 , wherein the brain or central nervous system (CNS) injury or condition is ischemic stroke or hemorrhagic stroke.

4. The method of claim 3 , wherein the compound or pharmaceutically acceptable salt thereof is administered within 48 hours of the stroke.

5. The method of claim 1 , wherein neuroprotection or neurorestoration is increased in the patient as compared with an untreated patient.

6. The method of claim 5 , wherein the increased neuroprotection or neurorestoration decreases the recovery period after the ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, or transient ischemic attacks (TIA) as compared with an untreated patient.

7. A method of treating a neurodegenerative condition, or a condition mediated by a brain injury or a neurodegenerative condition, comprising administering to a patient in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable composition thereof.

8. The method of claim 7 , wherein the compound is

9. The method of claim 7 , wherein the neurodegenerative condition is caused by a traumatic brain injury, concussion, stroke, partial or total spinal cord transection, malnutrition, a toxic neuropathy, a meningoencephalopathy, a genetic disorder, or age-related neurodegeneration.

10. The method of claim 7 , wherein the neurodegenerative condition is selected from Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD), Multiple Sclerosis (MS), amyotrophic lateral sclerosis (ALS), or chronic traumatic encephalopathy (CTE).

11. The method of claim 7 , wherein the neurodegenerative condition is Alzheimer's Disease.

12. The method of claim 7 , wherein the neurodegenerative condition is Parkinson's Disease.

13. The method of claim 7 , wherein the condition mediated by a brain injury or a neurodegenerative condition is selected from deafness, dry eyes, memory loss, cognitive difficulties or deficit in cognition, deficit in CNS function, or deficit in learning.

14. A method of treating a heart or cardiovascular disease, comprising administering to a patient in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable composition thereof;
wherein the heart or cardiovascular disease is selected from heart disease, cardiovascular disease, cardiac ischemia, arrhythmia, cardiac ischemia, or myocardial infarction.

15. A method of treating a disease or condition, comprising administering to a patient in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable composition thereof;
wherein the disease or condition is selected from an autoimmune disease or condition, glaucoma, an otic disorder, progressive hearing loss, tinnitus, collateral brain damage associated with radiation cancer therapy or migraine treatment, epilepsy, pain control, pain mediated by the CNS, neuropathic pain, inflammatory pain, or acute pain.

16. The method of claim 15 , wherein the disease or condition is an otic disorder.

17. The method of claim 15 , wherein the disease or condition is pain control, pain mediated by the CNS, neuropathic pain, inflammatory pain, or acute pain.

18. A method of increasing cardioprotection or regeneration of damaged heart tissue in a patient who has suffered a cardiac ischemia or myocardial infarction, comprising administering to a patient in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable composition thereof.

Assignees

• Astrocyte Pharmaceuticals Inc
• Univ Texas
• The Board Of Regents Of The Univ Of Texas Systems

Inventors

• Korinek William S
• Lechleiter James D
• Liston Theodore E

Classifications

• A61K31/52 Primary

  Purines, e.g. adenine · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K31/7076 Primary

  containing purines, e.g. adenosine, adenylic acid · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title